β-globin restored autologous hematopoietic stem cells

BIOLOGICAL3 trials

Sponsors

Shenzhen Hemogen

Conditions

Β-thalassemiaβ-thalassemia

Early Phase 1

Safety and Efficacy Evaluation of β-globin Restored Autologous Hematopoietic Stem Cells in β-thalassemia Major Patients

RecruitingNCT05745532

Shenzhen Hemogenβ-thalassemia

Start: 2020-12-01End: 2025-12-30Target: 10Updated: 2024-11-29

the Safety and Efficacy Evaluation of HGI-001 Injection in Patients With Transfusion-Dependent β-Thalassemia

RecruitingNCT05864170

Shenzhen Hemogenβ-thalassemia

Start: 2022-05-27End: 2025-12-30Target: 3Updated: 2024-11-29

Phase 1

Evaluating Safety and Efficacy of Lentiviral-transduced CD34+ HSCs in Β-thalassaemia Patients.

RecruitingNCT06655662

Shenzhen HemogenΒ-thalassemia

Start: 2024-06-12End: 2026-12-31Target: 8Updated: 2024-10-23